“The next chapter of VBC will be defined by how well we manage complexity, not just cost. Genetic testing, molecular diagnostics, and precision medicine are advancing faster than most organizations can evaluate them.”
Bill Kerr, CEO
“The organizations that integrate diagnostic intelligence into their value-based frameworks will be the ones that ultimately deliver on the promise of better care at lower cost. Without that layer, value-based care remains more aspiration than execution.”
In this First Report Managed Care article, leaders were asked to reflect on how the industry has evolved—and why success over the next 20 years will depend on moving from payment reform to the infrastructure, data, and care models needed to deliver measurable outcomes.
Avalon Health Care CEO Bill Kerr argues that value-based care has stalled not from lack of intent, but from a critical blind spot around diagnostic intelligence. Kerr’s call to action for 2026 is direct — health plans must embed evidence-based protocols and real-time clinical data into their lab benefit strategies so every test has a clear line of sight to a patient outcome. As precision medicine and molecular diagnostics accelerate, the plans that integrate diagnostic intelligence into their value-based frameworks will be the ones that finally move VBC from aspiration to execution.
Read the full article at First Report Managed Care.
